tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

SPRY Stock Latest News

ARS Pharmaceuticals submits response for neffy MA, partners with CSL Seqirus
The FlyARS Pharmaceuticals submits response for neffy MA, partners with CSL Seqirus
3d ago
SPRY
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
PremiumPress Releases
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
3d ago
SPRY
Insider Trading: ARS Pharmaceuticals’ (NASDAQ:SPRY) Insiders Buy Shares Worth $679K
PremiumMarket News
Insider Trading: ARS Pharmaceuticals’ (NASDAQ:SPRY) Insiders Buy Shares Worth $679K
8d ago
SPRY
ARS Pharmaceuticals submits response to FDA’s CRL for neffy nasal spray
PremiumThe Fly
ARS Pharmaceuticals submits response to FDA’s CRL for neffy nasal spray
30d ago
SPRY
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
PremiumPress Releases
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
30d ago
SPRY
Ars Pharmaceuticals’ Merger May Limit Use of Net Operating Losses, Impacting Future Financials
PremiumCompany AnnouncementsArs Pharmaceuticals’ Merger May Limit Use of Net Operating Losses, Impacting Future Financials
1M ago
SPRY
ARS Pharmaceuticals reports FY23 EPS (57c), consensus (14c)
PremiumThe Fly
ARS Pharmaceuticals reports FY23 EPS (57c), consensus (14c)
1M ago
SPRY
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
PremiumPress Releases
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
1M ago
SPRY
SPRY Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
SPRY Upcoming Earnings Report: What to Expect?
1M ago
SPRY
ARS Pharmaceuticals Updates Stakeholders with New Presentation
PremiumCompany Announcements
ARS Pharmaceuticals Updates Stakeholders with New Presentation
2M ago
8K
SPRY
ARS Pharmaceuticals to hold virtual investor day
PremiumThe Fly
ARS Pharmaceuticals to hold virtual investor day
2M ago
SPRY
ARS Pharmaceuticals to hold virtual investor day
PremiumThe Fly
ARS Pharmaceuticals to hold virtual investor day
2M ago
SPRY
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
PremiumPress ReleasesARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
2M ago
SPRY
Lyft upgraded, Philip Morris downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Lyft upgraded, Philip Morris downgraded: Wall Street’s top analyst calls
2M ago
T
CC
ARS Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
PremiumThe Fly
ARS Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
2M ago
SPRY
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
PremiumPress Releases
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
2M ago
SPRY
ARS Pharmaceuticals reports neffy meets primary endpoints in Phase 2 study
PremiumThe Fly
ARS Pharmaceuticals reports neffy meets primary endpoints in Phase 2 study
2M ago
SPRY
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
PremiumPress Releases
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
2M ago
SPRY
ARS Pharmaceuticals upgraded to Outperform from Market Perform at William Blair
PremiumThe Fly
ARS Pharmaceuticals upgraded to Outperform from Market Perform at William Blair
2M ago
SPRY
ARS Pharmaceuticals announces results from repeat dosing study of neffy
PremiumThe FlyARS Pharmaceuticals announces results from repeat dosing study of neffy
2M ago
SPRY
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
PremiumPress Releases
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
2M ago
SPRY
ARS Pharmaceuticals to present efficacy data for neffy at 2024 AAAAI meeting
PremiumThe Fly
ARS Pharmaceuticals to present efficacy data for neffy at 2024 AAAAI meeting
3M ago
SPRY

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >